Active Ingredient History
Octreotide (SMS 201-995, Sandostatin) is an octapeptide that exerts pharmacologic actions similar to the natural hormone, somatostatin. It was developed by Bauer and co-authors at Sandoz. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses LH response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide. By virtue of these pharmacological actions, Sandostatin has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). Sandostatin substantially reduces growth hormone and/or IGF-I (somatomedin C) levels in patients with acromegaly. A radioactively labelled analogue has been used to visualize somatostatin receptors in a GRF-secreting human tumour. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Abdominal Pain (Phase 2/Phase 3)
Acromegaly ()
Acute Kidney Injury (Early Phase 1)
Adenoma (Phase 4)
Adenoma, Islet Cell (Phase 2)
Anemia (Phase 2/Phase 3)
Angiodysplasia (Phase 2/Phase 3)
Anus Neoplasms (Phase 3)
Ascites (Phase 4)
Bile Duct Neoplasms (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoid Tumor (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Islet Cell (Phase 2)
Carcinoma, Merkel Cell (Phase 1)
Carcinoma, Neuroendocrine (Phase 2)
Chylothorax (Early Phase 1)
Colonic Neoplasms (Phase 4)
Colorectal Neoplasms (Phase 3)
Congenital Hyperinsulinism (Phase 2)
Constipation (Phase 4)
Diabetes Mellitus (Phase 3)
Diabetes Mellitus, Type 2 (Phase 1)
Diabetic Retinopathy (Phase 3)
Diarrhea (Phase 4)
Dilatation, Pathologic (Phase 2)
Disease Progression (Phase 2)
Drug Interactions (Phase 1)
Endometrial Neoplasms (Phase 3)
Enteritis (Phase 3)
Esophageal and Gastric Varices (Phase 4)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 3)
Fibrosis (Phase 4)
Fistula (Phase 1)
Gastrointestinal Hemorrhage (Phase 2/Phase 3)
Gastrointestinal Neoplasms (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
General Surgery (Phase 3)
Glomerular Filtration Rate (Phase 2/Phase 3)
Glucagon (Phase 1)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Hematemesis (Phase 4)
Hepatomegaly (Phase 2/Phase 3)
Hepatorenal Syndrome (Phase 2/Phase 3)
Hyperinsulinism (Phase 1)
Hyperphagia (Phase 3)
Hypertension, Portal (Phase 4)
Hypoglycemia (Phase 3)
Hypotension, Orthostatic (Phase 1)
Idiopathic Pulmonary Fibrosis (Phase 1/Phase 2)
Insulin (Phase 2)
Insulin Resistance (Phase 1)
Intestinal Neoplasms (Phase 4)
Intestinal Obstruction (Phase 2)
Intraabdominal Infections (Phase 1)
Irritable Bowel Syndrome (Phase 1)
Kidney Diseases (Phase 4)
Liver (Phase 2)
Liver Cirrhosis (Phase 4)
Liver Diseases (Phase 2/Phase 3)
Liver Neoplasms (Phase 2)
Liver Transplantation (Phase 2)
Lung Neoplasms (Phase 1)
Lymphangioleiomyomatosis (Phase 2)
Lymphangiomyoma (Phase 2)
Lymphatic Diseases (Early Phase 1)
Lymphoid Tissue (Phase 2)
Lymphoma (Phase 2)
Malignant Carcinoid Syndrome (Phase 4)
Melanoma (Phase 2)
Melena (Phase 4)
Meningioma (Phase 2)
Migraine Disorders (Phase 1/Phase 2)
Multiple Myeloma (Phase 2)
Nausea (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms ()
Neoplastic Syndromes, Hereditary (Phase 2)
Neuroendocrine Tumors (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 1)
Obesity (Phase 4)
Octreotide (Phase 2)
Orthostatic Intolerance (Phase 1/Phase 2)
Ovarian Neoplasms (Phase 3)
Pancreatic Fistula (Phase 4)
Pancreatic Neoplasms (Phase 3)
Paraganglioma (Phase 1)
Peritoneal Neoplasms (Phase 2)
Pheochromocytoma (Phase 2)
Pituitary Neoplasms (Phase 4)
Pleural Effusion (Phase 2)
Polycystic Kidney, Autosomal Dominant (Phase 2/Phase 3)
Polycystic Kidney Diseases (Phase 2/Phase 3)
Prader-Willi Syndrome (Phase 3)
Prediabetic State (Phase 1)
Prostatic Neoplasms (Phase 3)
Pure Autonomic Failure (Phase 1)
Renal Insufficiency (Phase 2)
Salivary Gland Fistula (Phase 2)
Sarcoma (Phase 3)
Seroma (Phase 4)
Sputum (Phase 2)
Squamous Intraepithelial Lesions (Phase 2)
Stomach Neoplasms (Phase 3)
Tachycardia (Phase 1/Phase 2)
Telangiectasia, Hereditary Hemorrhagic (Phase 2)
Thymoma (Phase 2)
Thyroid Neoplasms (Phase 1)
Uterine Cervical Neoplasms (Phase 3)
Vaginal Neoplasms (Phase 3)
Vascular Malformations (Phase 2/Phase 3)
Vascular Stiffness (Early Phase 1)
Vipoma (Phase 2)
Vulvar Neoplasms (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue